<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39250623</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1998-3751</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Indian journal of pharmacology</Title><ISOAbbreviation>Indian J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Pharmacological benefits of durva swaras (Cynodon dactylon L. Pers.) administration in APAP-induced liver injury model of mice - Assessment by metabolic and inflammatory markers.</ArticleTitle><Pagination><StartPage>260</StartPage><EndPage>267</EndPage><MedlinePgn>260-267</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijp.ijp_133_24</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Liver derangement underlies the development of metabolic syndrome in perimenopause. Previously, we have observed that durva swaras (DS) improved metabolic-associated fatty liver disease (MAFLD) and abnormal liver enzymes (aspartate aminotransferase and alanine aminotransferase) along with other complications of menopause in ovariectomized rats. We aimed to decipher the hepatoprotective mechanisms of DS in acetaminophen (APAP)-induced liver injury model, which is analogous to the pathophysiology of MAFLD.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Male Swiss albino mice were distributed into three groups at random. Group I (Control) was administered with vehicle (distilled water) for 7 days. Group II (APAP) received vehicle for the first 6 days and APAP (350 mg/kg - single dose) on the 7th day. Group III (APAP + D) received test compound DS (quality complied) at a dose of 133 mg/kg for 6 days and APAP (350 mg/kg - single dose) on the 7th day. Subsequently, blood and liver tissues were subjected to biochemical, ultrastructural, and gene expression analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DS pretreatment protected the liver from APAP-induced disruption of sinusoids and necrosis. DS prevented the elevation of liver enzymes - AST and ALT induced by APAP. Importantly, DS inhibited the APAP-elicited increase in messenger ribonucleic acid levels of hepatic nuclear factor-kappa beta (NF-κB) and pro-inflammatory cytokines, namely interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha. Moreover, DS activated gene expression of nuclear factor erythroid 2-related factor 2 and liver-X-receptor-alpha (LXR-α) to combat the liver damage.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">DS hinders APAP-induced liver damage by activating LXR-α and inhibiting the NF-κB-associated pro-inflammatory cytokine gene expression. These observations confirm the protective role of DS in metabolic dysfunction-associated liver conditions.</AbstractText><CopyrightInformation>Copyright © 2024 Copyright: © 2024 Indian Journal of Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sindhoora</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Drug and Food Safety, ICMR-National Institute of Nutrition, Tarnaka, Jamai-Osmania, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Vandana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Senior Scientist, Department of Innovation and R&amp;D, Sarvotham Care Limited, Secunderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mungamuri</LastName><ForeName>Sathish Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Division of Drug and Food Safety, ICMR-National Institute of Nutrition, Tarnaka, Jamai-Osmania, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bharatraj</LastName><ForeName>Dinesh Kumar</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Division of Drug and Food Safety, ICMR-National Institute of Nutrition, Tarnaka, Jamai-Osmania, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Pharmacol</MedlineTA><NlmUniqueID>7902477</NlmUniqueID><ISSNLinking>0253-7613</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>362O9ITL9D</RegistryNumber><NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.6.1.2</RegistryNumber><NameOfSubstance UI="D000410">Alanine Transaminase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.6.1.1</RegistryNumber><NameOfSubstance UI="D001219">Aspartate Aminotransferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="Y">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082" MajorTopicYN="Y">Acetaminophen</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000410" MajorTopicYN="N">Alanine Transaminase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001219" MajorTopicYN="N">Aspartate Aminotransferases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>14</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39250623</ArticleId><ArticleId IdType="doi">10.4103/ijp.ijp_133_24</ArticleId><ArticleId IdType="pii">01363791-202407000-00005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jaroenlapnopparat A, Charoenngam N, Ponvilawan B, Mariano M, Thongpiya J, Yingchoncharoen P. Menopause is associated with increased prevalence of nonalcoholic fatty liver disease:A systematic review and meta-analysis. Menopause 2023;30:348–54.</Citation></Reference><Reference><Citation>Matsui S, Yasui T, Kasai K, Keyama K, Kato T, Uemura H, et al. Changes of liver enzymes and triglyceride during the menopausal transition in Japanese women. J Obstet Gynaecol 2016;36:806–11.</Citation></Reference><Reference><Citation>Singh V, Singh A, Quadri SS, Surekha MV, Mahesh J, Rao B, et al. Pharmacological properties of Durva Swaras (Cynodon dactylon L. Pers.) In an ovariectomised rat model mimicking chronic menopausal syndrome. Biomed Pharmacother 2021;142:111976.</Citation></Reference><Reference><Citation>Kubes P, Jenne C. Immune responses in the liver. Annu Rev Immunol 2018;36:247–77.</Citation></Reference><Reference><Citation>Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature 2017;542:177–85.</Citation></Reference><Reference><Citation>Tao L, Ren X, Zhai W, Chen Z. Progress and prospects of non-canonical NF-κB signaling pathway in the regulation of liver diseases. Molecules 2022;27:4275.</Citation></Reference><Reference><Citation>Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003;9:213–9.</Citation></Reference><Reference><Citation>Rudraiah S, Zhang X, Wang L. Nuclear receptors as therapeutic targets in liver disease:Are we there yet?. Annu Rev Pharmacol Toxicol 2016;56:605–26.</Citation></Reference><Reference><Citation>Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article:Drug-induced liver injury in the context of nonalcoholic fatty liver disease –A physiopathological and clinical integrated view. Aliment Pharmacol Ther 2018;48:892–913.</Citation></Reference><Reference><Citation>Singh V, Singh A, Singh IP, Kumar BD. Phytomedicinal properties of Cynodon dactylon (L.) Pers. (Durva) in its traditional preparation and extracts. Phytomed Plus 2021;1:100020.</Citation></Reference><Reference><Citation>Karnovsky M. A formaldehyde-glutaraldehyde fixative of high osmolality for use in electron-microscopy. J Cell Biol 1964;27:137–138A.</Citation></Reference><Reference><Citation>Glauert AM. Fixation, Dehydration and Embedding of Biological Specimens. 1st ed. North Holland American Elsevier: Elsevier Science; 1984.</Citation></Reference><Reference><Citation>Walker RM, Racz WJ, McElligott TF. Scanning electron microscopic examination of acetaminophen-induced hepatotoxicity and congestion in mice. Am J Pathol 1983;113:321–30.</Citation></Reference><Reference><Citation>Kolaric TO, Nincevic V, Kuna L, Duspara K, Bojanic K, Vukadin S, et al. Drug-induced fatty liver disease: Pathogenesis and treatment. J Clin Transl Hepatol 2021;9:731–7.</Citation></Reference><Reference><Citation>Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab 2015;19:597–601.</Citation></Reference><Reference><Citation>Luedde T, Schwabe RF. NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011;8:108–18.</Citation></Reference><Reference><Citation>Ghisletti S, Huang W, Jepsen K, Benner C, Hardiman G, Rosenfeld MG, et al. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev 2009;23:681–93.</Citation></Reference><Reference><Citation>Saini SP, Zhang B, Niu Y, Jiang M, Gao J, Zhai Y, et al. Activation of liver X receptor increases acetaminophen clearance and prevents its toxicity in mice. Hepatology 2011;54:2208–17.</Citation></Reference><Reference><Citation>Yan C, Zhang Y, Zhang X, Aa J, Wang G, Xie Y. Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice. Biomed Pharmacother 2018;105:274–81.</Citation></Reference><Reference><Citation>Sotiropoulou M, Katsaros I, Vailas M, Lidoriki I, Papatheodoridis GV, Kostomitsopoulos NG, et al. Nonalcoholic fatty liver disease:The role of quercetin and its therapeutic implications. Saudi J Gastroenterol 2021;27:319–30.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>